source
- Setbacks for Novartis; Anthropic looks for a dealmaker; and moreWelcome back to another edition of Endpoints Weekly! While it is still technically summer, the season is starting to turn now that we’re past Labor Day. It will be a sprint to Thanksgiving, and we’…Endpoints · 14m ago↗ source
- Revolution Medicines secures FDA approval for Rasonque, a RAS inhibitor targeting advanced pancreatic cancerRevolution Medicines announced FDA approval of its RAS inhibitor Rasonque for patients with advanced pancreatic cancer, marking a milestone for the company. The approval is seen as a breakthrough…